News and Press Releases

X-Chem Strengthens Its Data-Driven Discovery Services

With new CBO appointment industry veteran Paul Davie joins X-Chem executive team to lead strategic growth and partnerships 20 June 2024 -- Massachusetts, US -- Small molecule drug discovery acceleration...

Category: Biotechnology, Drug Discovery, Pharmaceutical
Posted: June 20, 2024

100 Beaver Street Waltham, MA 02453

Enterprise Therapeutics appoints Dr Renu Gupta as chief medical officer and Dr Janet Hammond as non-executive director

Appointments bring additional respiratory and late clinical-stage drug development experience as company commences Phase 2a clinical trial of its lead asset 17 June 2024, Brighton, UK -: Enterprise Therapeutics Ltd...

Category: Biotechnology, Pharmaceutical
Posted: June 17, 2024

Sussex Innovation Centre, University of Sussex, Science Park Square, Falmer, Brighton, BN1 9SB, UK

China’s Innovent holds potential to change pancreatic cancer treatment landscape with bispecific antibody IBI389, says GlobalData

14 June 2024 - China-based Innovent Biologics recently presented phase 1 study results of its first-in-class anti-CLDN18.2/CD3 bispecific antibody (IBI389) for the treatment of advanced pancreatic cancer at the 2024...

Category: Biotechnology, Pharmaceutical
Posted: June 14, 2024

GlobalData, John Carpenter House, 7 Carmelite Street, London, EC4Y 0BS, United Kingdom

Tapinarof may mark Dermavant’s first atopic dermatitis approval, says GlobalData

Dermavant's VTAMA (tapinarof), a nonsteroidal, topical AhR-modulating agent, achieved positive phase 3 trial results in atopic dermatitis patients aged two and above, leading to Food and Drug Administration (FDA) acceptance...

Category: Drug Discovery, Pharmaceutical
Posted: June 13, 2024

GlobalData, John Carpenter House, 7 Carmelite Street, London, EC4Y 0BS, United Kingdom

Formycon reports on the results of the annual general meeting

Management provides detailed report on financial year 2023 and current company performance. Shareholders approve all agenda items and formally approve the acts of the members of the management board and...

Category: BioManufacturing
Posted: June 13, 2024

Formycon AG, Fraunhoferstraße 15, 82152 Martinsried/Planegg, Germany

Deep Genomics Expands Executive Leadership and Operations in Latest Strategic Growth Initiative  

Company announces executive new hires and marks significant momentum with Cambridge, Massachusetts, US, site opening and Toronto, Canada, office expansion   13 June 2024 -- Massachusetts, US -- Deep Genomics, the...

Category: Biotechnology, Other, Pharmaceutical
Posted: June 13, 2024

480 University Ave, Suite 1300 Toronto, Ontario, Canada, M5G 1V2

IQVIA Launches “One Home” Clinical Trial Technology Platform – Solves Challenges and Reduces Overload at Sites

Bold initiative to boost the capacity of research sites enters Beta testing and piloting 12 June 2024 -- North Carolina, US -- IQVIA today announced the launch of One Home...

Category: Clinical Trials, Drug Discovery, Other
Posted: June 12, 2024

CluePoints, a leading provider of AI-driven software solutions for Clinical Data Review, receives significant investment for continued growth from EQT

CluePoints is a cloud-based software platform for Risk-Based Quality Management (RBQM) and data quality oversight in clinical trials, designed to enable safer and more efficient processes and improving data integrity...

Category: Biotechnology, Clinical Trials
Posted: June 12, 2024

1000 Continental Drive, Suite 240, King of Prussia, PA 19406

SciRhom Announces Approval of First Clinical Trial Application for a Novel iRhom2-targeting Antibody Against Autoimmune Diseases

12 June 2024 -- Munich, Germany -- SciRhom GmbH, a biopharmaceutical company pioneering the development of first-in-class therapeutic antibodies, announced today the approval of a clinical trial application (CTA) by...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 12, 2024

Am Klopferspitz 19 82152 Planegg/Martinsried Germany

Asgard Therapeutics selects Exothera to bring their viral vector-based immunotherapy candidate AT-108 to clinical trial stage

11 June 2024 -- Lund, Sweden -- Asgard Therapeutics, a privately held biotech company pioneering in vivo direct cell reprogramming for cancer immunotherapy, today announced it selected Exothera, a leading...

Category: Biotechnology, Clinical Trials, Drug Discovery
Posted: June 11, 2024

Medicon Village, 223 81 Lund, Sweden

Newcells Biotech strengthens executive and US team with key appointments

Dr Valeria Chichagova appointed as director of technology, Dr Colin Brown as chief scientific officer, and Professor Lyle Armstrong as scientific advisor New US commercial appointments also announced to meet...

Category: Biotechnology
Posted: June 11, 2024

Newcells Biotech, The Biophere, Drayman's Way, newcastle Helix, Newcastle-upon-Tyne, NE4 5BX

CRISM Therapeutics Corp to continue pioneering R&D at PHTA following listing on the London Stock Exchange

11 June 2024 -- Birmingham, UK -- CRISM Therapeutics Corporation a UK-based pharmaceutical company focused on improving the clinical performance of cancer treatments for solid tumours, has raised £2.0m to...

Category: Biotechnology, Clinical Trials, Drug Delivery, Pharmaceutical
Posted: June 11, 2024

Kingston Chambers, PO Box 173, Road Town Tortola, British Virgin Islands

Kite’s TECARTUS (Brexucabtagene Autoelucel) Demonstrates Sustained Overall Survival in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia

After more than four years of follow-up in the pivotal ZUMA-3 study, median overall survival was 26 months and four-year overall survival rate was 40% at 48 months Survival benefit...

Category: Biotechnology, Clinical Trials, Pharmaceutical
Posted: June 3, 2024

2400 Broadway Santa Monica, CA 90404

TECVAYLI▼ (teclistamab) shows sustained deep and durable responses in patients with relapsed or refractory multiple myeloma

New MajesTEC-1 data show a median duration of response of 24 months, with responses deepening, including in patients who switched to biweekly dosing Separate analyses from the MajesTEC-1 and OPTec...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Janssen-Cilag Limited 50-100 Holmers Farm Way High Wycombe Buckinghamshire HP12 4EG

First participant dosed in research study investigating the effects of BPL-003, a novel formulation of 5-MeO-DMT, on the human brain

The study is the first of its kind to assess the effects of 5-MeO-DMT in the human brain and will investigate the neurophysiological effects of BPL-003, Beckley Psytech’s novel synthetic...

Category: Clinical Trials, Drug Discovery, Pharmaceutical
Posted: June 3, 2024

Beckley Park Beckley OXFORD, OX3 9SY United Kingdom